Dallas Williams

1.4k total citations
24 papers, 966 citations indexed

About

Dallas Williams is a scholar working on Surgery, Pulmonary and Respiratory Medicine and Epidemiology. According to data from OpenAlex, Dallas Williams has authored 24 papers receiving a total of 966 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Surgery, 8 papers in Pulmonary and Respiratory Medicine and 7 papers in Epidemiology. Recurrent topics in Dallas Williams's work include Bladder and Urothelial Cancer Treatments (12 papers), Multiple and Secondary Primary Cancers (5 papers) and Urinary and Genital Oncology Studies (5 papers). Dallas Williams is often cited by papers focused on Bladder and Urothelial Cancer Treatments (12 papers), Multiple and Secondary Primary Cancers (5 papers) and Urinary and Genital Oncology Studies (5 papers). Dallas Williams collaborates with scholars based in United States and Spain. Dallas Williams's co-authors include Randall E. Millikan, Colin P. Dinney, Lance C. Pagliaro, Christopher J. Logothetis, Peter F. Thall, Sijin Wen, Danai Daliani, H. Barton Grossman, Arlene O. Siefker‐Radtke and Curtis A. Pettaway and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer.

In The Last Decade

Dallas Williams

22 papers receiving 940 citations

Peers

Countries citing papers authored by Dallas Williams

Since Specialization

Citations

This map shows the geographic impact of Dallas Williams's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dallas Williams with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dallas Williams more than expected).

Fields of papers citing papers by Dallas Williams

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dallas Williams. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dallas Williams. The network helps show where Dallas Williams may publish in the future.

Co-authorship network of co-authors of Dallas Williams

This figure shows the co-authorship network connecting the top 25 collaborators of Dallas Williams. A scholar is included among the top collaborators of Dallas Williams based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dallas Williams. Dallas Williams is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Re: A phase 2 clinical trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine followed by cisplatin, gemcitabine, and ifosfamide in locally advanced urothelial cancer: Final results 2013 ·The Journal of Urology ·Arlene O. Siefker‐Radtke, Colin P. Dinney, Yali Shen, Dallas Williams, (unknown), H. Barton Grossman, Randall E. Millikan	0
2	A phase 2 clinical trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine followed by cisplatin, gemcitabine, and ifosfamide in locally advanced urothelial cancer 2012 ·Cancer ·Arlene O. Siefker‐Radtke, Colin P. Dinney, Yu Shen, Dallas Williams, Ashish M. Kamat, H. Barton Grossman, Randall E. Millikan	66
3	Phase II Clinical Trial of Neoadjuvant Alternating Doublet Chemotherapy With Ifosfamide/Doxorubicin and Etoposide/Cisplatin in Small-Cell Urothelial Cancer 2009 ·Journal of Clinical Oncology ·Arlene O. Siefker‐Radtke, Ashish M. Kamat, H. Barton Grossman, Dallas Williams, Wei Qiao, Peter F. Thall, Colin P. Dinney, Randall E. Millikan	116
4	A phase II randomized four-regimen selection trial incorporating response for sequential chemotherapy in metastatic, unresectable urothelial cancer: Final results from the M. D. Anderson Cancer Center 2009 ·Journal of Clinical Oncology ·Arlene O. Siefker‐Radtke, Ashish M. Kamat, Dallas Williams, Nizar M. Tannir, (unknown), Lance C. Pagliaro, Colin P. Dinney, Randall E. Millikan	4
5	Neoadjuvant Platelet Derived Growth Factor Receptor Inhibitor Therapy Combined With Docetaxel and Androgen Ablation for High Risk Localized Prostate Cancer 2008 ·The Journal of Urology ·Paul Mathew, Louis L. Pisters, Christopher G. Wood, John Papadopoulos, Dallas Williams, Peter F. Thall, Sijin Wen, (unknown), Carol J. Oborn, Robert R. Langley, Isaiah J. Fidler, Curtis A. Pettaway	30
6	Adaptive Therapy for Androgen-Independent Prostate Cancer: A Randomized Selection Trial of Four Regimens 2007 ·JNCI Journal of the National Cancer Institute ·(unknown), Christopher J. Logothetis, Lance C. Pagliaro, Sijin Wen, Matthew A. Brown, Dallas Williams, R. E. Millikan	46
7	602: Neoadjuvant Paclitaxel (P), Ifosfamide (I), and Cisplatin (C) Chemotherapy Prior to Inguinal/Pelvic Lymphadenectomy for Stage Tany, N2-3, M0 Souamous Carcinoma (SCC) of the Penis 2006 ·The Journal of Urology ·Lance C. Pagliaro, Dallas Williams, Danai Daliani, Shi‐Ming Tu, (unknown), Lior Heller, Curtis A. Pettaway	6
8	1240: Prospective Evidence Supporting the Utility of Neooadjuvant Chemotherapy in Small Cell Urothelial Cancer: Preliminary Results from A Phase II Clinical Trial at the M.D. Anderson Cancer Center 2006 ·The Journal of Urology ·Arlene O. Siefker‐Radtke, Ashish M. Kamat, H. Barton Grossman, Dallas Williams, Colin P. Dinney, Randall E. Millikan	2
9	Phase I study of ispinesib (SB-715992) in combination with docetaxel in patients with advanced solid tumors. 2005 ·Clinical Cancer Research ·Sarah P. Blagden, (unknown), R. Molife, Miranda Payne, Alison Reid, Andrew Protheroe, Steven J. Kathman, Dallas Williams, Carolyn J. Bowen, Jeffrey P. Hodge, (unknown), Johann S. de Bono, Mark R. Middleton	1
10	Randomized, adaptive, phase II selection trial of four chemotherapy regimens in androgen independent prostate cancer (AIPC) 2004 ·Journal of Clinical Oncology ·R. E. Millikan, Peter F. Thall, Lance C. Pagliaro, Dallas Williams, Matthew A. Brown, C. Logothetis	1
11	Implementation of a novel statistical design to evaluate successive treatment courses for metastatic transitional cell carcinoma. A Phase II trial at the M. D. Anderson Cancer Center 2004 ·Journal of Clinical Oncology ·Arlene O. Siefker‐Radtke, Peter F. Thall, Nizar M. Tannir, (unknown), Lance C. Pagliaro, Dallas Williams, Randall E. Millikan	2
12	Implementation of a novel statistical design to evaluate successive treatment courses for metastatic transitional cell carcinoma. A Phase II trial at the M. D. Anderson Cancer Center 2004 ·Journal of Clinical Oncology ·Arlene O. Siefker‐Radtke, (unknown), Nizar M. Tannir, (unknown), Lance C. Pagliaro, Dallas Williams, R. E. Millikan	1
13	Randomized clinical trial and economic analysis of four-layer compression bandaging for venous ulcers [Commentary] 2003 ·ORCA Online Research @Cardiff ·Stuart Enoch, Dallas Williams, Patricia Price, Keith G Harding	2
14	A Phase I/II study of strontium‐89 combined with gemcitabine in the treatment of patients with androgen independent prostate carcinoma and bone metastases 2003 ·Cancer ·Lance C. Pagliaro, Ebrahim S. Delpassand, Dallas Williams, Randall E. Millikan, Shi‐Ming Tu, Christopher J. Logothetis	22
15	Treatment of refractory urothelial carcinoma with alternating paclitaxel, methotrexate, cisplatin (TMP) and 5-fluorouracil, α-interferon, cisplatin (FAP) 2003 ·Urologic Oncology Seminars and Original Investigations ·Shi‐Ming Tu, Randall E. Millikan, Lance C. Pagliaro, Danai Daliani, Christos N. Papandreou, Jeri Kim, Dung‐Tsa Chen, Dallas Williams, Christopher J. Logothetis	1
16	Repeated Intravesical Instillations of an Adenoviral Vector in Patients With Locally Advanced Bladder Cancer: A Phase I Study of p53 Gene Therapy 2003 ·Journal of Clinical Oncology ·Lance C. Pagliaro, Afsaneh Keyhani, Dallas Williams, Denise M. Woods, (unknown), Paul Perrotte, Joel W. Slaton, James A. Merritt, H. Barton Grossman, Colin P. Dinney	99
17	Phase III Trial of Fluorouracil, Interferon Alfa-2b, and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Metastatic or Unresectable Urothelial Cancer 2002 ·Journal of Clinical Oncology ·Arlene O. Siefker‐Radtke, Randall E. Millikan, Shi‐Ming Tu, Dennis F. Moore, Terry L. Smith, Dallas Williams, Christopher J. Logothetis	28
18	Cisplatin, Gemcitabine, and Ifosfamide As Weekly Therapy: A Feasibility and Phase II Study of Salvage Treatment for Advanced Transitional-Cell Carcinoma 2002 ·Journal of Clinical Oncology ·Lance C. Pagliaro, Randall E. Millikan, Shi‐Ming Tu, Dallas Williams, Danai Daliani, Christos N. Papandreou, Christopher J. Logothetis	53
19	Gemcitabine modulation of alkylator therapy 2001 ·Cancer ·Randall E. Millikan, William Plunkett, Terry Smith, Dallas Williams, C. Logothetis	13
20	Integrated Therapy for Locally Advanced Bladder Cancer: Final Report of a Randomized Trial of Cystectomy Plus Adjuvant M-VAC Versus Cystectomy With Both Preoperative and Postoperative M-VAC 2001 ·Journal of Clinical Oncology ·Randall E. Millikan, Colin P. Dinney, David A. Swanson, (unknown), Jae Y. Ro, Terry Smith, Dallas Williams, Christopher J. Logothetis	205

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact